What is Intellia Therapeutics Inc. (NTLA) Stock Return on Shareholders’ Capital?

Intellia Therapeutics Inc. (NASDAQ: NTLA) stock fell -8.74% on Friday to $65.43 against a previous-day closing price of $71.70. With 2.91 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.32 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $65.89 whereas the lowest price it dropped to was $57.63. The 52-week range on NTLA shows that it touched its highest point at $180.59 and its lowest point at $37.08 during that stretch. It currently has a 1-year price target of $128.68. Beta for the stock currently stands at 2.02.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NTLA was down-trending over the past week, with a drop of -0.35%, but this was up by 8.13% over a month. Three-month performance surged to 17.47% while six-month performance fell -31.41%. The stock lost -55.47% in the past year, while it has lost -44.66% so far this year. A look at the trailing 12-month EPS for NTLA yields -5.04 with Next year EPS estimates of -5.97. For the next quarter, that number is -1.31. This implies an EPS growth rate of -57.60% for this year and -2.40% for next year. EPS is expected to grow by 30.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -21.60%.

Float and Shares Shorts:

At present, 74.75 million NTLA shares are outstanding with a float of 68.28 million shares on hand for trading. On Jul 14, 2022, short shares totaled 7.22 million, which was 9.51% higher than short shares on Jun 14, 2022. In addition to Dr. John M. Leonard M.D. as the firm’s Pres, CEO & Director, Mr. Glenn G. Goddard CPA serves as its Exec. VP, CFO & Treasurer.

Institutional Ownership:

Through their ownership of 86.25% of NTLA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 54.88% of NTLA, in contrast to 32.19% held by mutual funds. Shares owned by individuals account for 22.23%. As the largest shareholder in NTLA with 12.54% of the stake, ARK Investment Management LLC holds 9,514,580 shares worth 9,514,580. A second-largest stockholder of NTLA, The Vanguard Group, Inc., holds 6,208,104 shares, controlling over 8.18% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in NTLA, holding 4,916,381 shares or 6.48% stake. With a 8.86% stake in NTLA, the ARK Innovation ETF is the largest stakeholder. A total of 6,716,513 shares are owned by the mutual fund manager. The Nikko AM Global Umbrella Fund – A, which owns about 3.04% of NTLA stock, is the second-largest Mutual Fund holder. It holds 2,308,175 shares valued at 119.47 million. Vanguard Total Stock Market Index holds 2.65% of the stake in NTLA, owning 2,009,474 shares worth 104.01 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NTLA since 25 analysts follow the stock currently. There are 19 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 3 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NTLA analysts setting a high price target of $207.00 and a low target of $54.00, the average target price over the next 12 months is $129.91. Based on these targets, NTLA could surge 216.37% to reach the target high and fall by -17.47% to reach the target low. Reaching the average price target will result in a growth of 98.55% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. NTLA will report FY 2022 earnings on 03/15/2023. Analysts have provided yearly estimates in a range of -$4.22 being high and -$8.31 being low. For NTLA, this leads to a yearly average estimate of -$5.76. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Intellia Therapeutics Inc. surprised analysts by -$0.05 when it reported -$1.33 EPS against a consensus estimate of -$1.28. The surprise factor in the prior quarter was -$0.85. Based on analyst estimates, the high estimate for the next quarter is -$0.81 and the low estimate is -$2.07. The average estimate for the next quarter is thus -$1.28.

Summary of Insider Activity:

Insiders traded NTLA stock several times over the past three months with 8 Buys and 0 Sells. In these transactions, 38,393 shares were bought while 0 shares were sold. The number of buy transactions has increased to 39 while that of sell transactions has risen to 64 over the past year. The total number of shares bought during that period was 511,713 while 350,732 shares were sold.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]